Literature DB >> 3427331

Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases.

L R Baker1, W J Mallinson, M C Gregory, E A Menzies, W R Cattell, H N Whitfield, W F Hendry, J E Wickham, A M Joekes.   

Abstract

Sixty patients with idiopathic retroperitoneal fibrosis presenting between 1965 and 1984 are reviewed. Their mean age at presentation was 56 years and the male:female ratio was 3:1. The commonest presenting symptoms were flank and abdominal pain, weight loss, nausea and polyuria. Physical examination was usually normal, expect for the presence of hypertension. Anaemia and elevation of erythrocyte sedimentation rate were usually present. Proteinuria was found in less than a third of patients at presentation and significant bacteriuria was uncommon. The correct diagnosis was made or suspected in very few patients before referral. The cumulative actuarial survival rate was 86% at 1 year and 78% at 2 years. Seventeen patients died; they were significantly older and more uraemic at the time of referral than those who survived. A few patients did well with either corticosteroid therapy or ureterolysis alone. In the majority, both operation and steroid treatment were necessary. In bilateral obstruction with residual function in both kidneys, bilateral ureterolysis proved superior to unilateral operation (each followed by steroid therapy) in conserving renal function. Operation alone or steroid therapy alone should be considered in cases where steroids or surgery respectively present particular hazards. The less traumatic unilateral operation should be considered in poor risk patients and in those whose renal function is absent on one side. In many survivors, disease activity has persisted for many years. Life-long follow-up is recommended.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3427331     DOI: 10.1111/j.1464-410x.1987.tb05028.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  31 in total

1.  Follow-up of a case of retroperitoneal fibroses treated sequencially via right side autotransplant and left uterolysis with wrapper of posterior preperitoneal fat.

Authors:  G C Peñalver; T A Sánchez; D R Gonzalez; R A Antolin; A F Benites; L O Galvis
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Close relationship between autoimmune pancreatitis and multifocal fibrosclerosis.

Authors:  T Kamisawa; N Funata; Y Hayashi; K Tsuruta; A Okamoto; K Amemiya; N Egawa; H Nakajima
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 3.  Chronic periaortitis--a new interpretation of Ormond's disease.

Authors:  B Martina
Journal:  Urol Res       Date:  1990

4.  [Regression of retroperitoneal fibrosis by combination therapy with tamoxifen and steroids].

Authors:  J Allendorff; W Riegel; H Köhler
Journal:  Med Klin (Munich)       Date:  1997-07-15

5.  Retroperitoneal fibrosis.

Authors:  Anastasios Koulaouzidis; Shivaram Bhat; Karthy Gopal
Journal:  CMAJ       Date:  2007-10-23       Impact factor: 8.262

6.  Simultaneous bilateral subcutaneous pyelovesical bypass as a salvage procedure in refractory retroperitoneal fibrosis.

Authors:  Nicholas Haddad; Sero Andonian; Maurice Anidjar
Journal:  Can Urol Assoc J       Date:  2013 May-Jun       Impact factor: 1.862

Review 7.  Retroperitoneal fibrosis: a clinical and outcome analysis of 58 cases and review of literature.

Authors:  Hang Liu; Gejun Zhang; Yimeng Niu; Nan Jiang; Weiguo Xiao
Journal:  Rheumatol Int       Date:  2014-04-23       Impact factor: 2.631

Review 8.  Idiopathic retroperitoneal fibrosis.

Authors:  N Bullock
Journal:  BMJ       Date:  1988-07-23

9.  Retroperitoneal fibrosis as a cause of positive FDG PET/CT.

Authors:  Amar Mehta; Todd M Blodgett
Journal:  J Radiol Case Rep       Date:  2011-07-01

10.  Diagnosis and follow-up of idiopathic retroperitoneal fibrosis: role of (18)F-FDG-PET/CT and biochemical parameters in patients with renal involvement.

Authors:  Claudia Fofi; Daniela Prosperi; Laura Pettorini; Francescaromana Festuccia; Riccardo Pirisino; Valerio Lanni; Francesco Scopinaro; Giorgio Punzo; Paolo Menè
Journal:  Intern Emerg Med       Date:  2016-03-12       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.